Recombinant PI3-Kinase p85 α Monoclonal Antibody (AN301112L)
For research use only.
| Verified Samples |
Verified Samples in WB: HepG2 Verified Samples in IHC: Human placenta tissue |
| Dilution | IHC 1:200-1000, WB 1:1000-5000 |
| Isotype | IgG,κ |
| Host | Rabbit |
| Reactivity | Human, Mouse, Rat |
| Applications | WB, IHC |
| Clonality | Monoclonal;Recombinant |
| Immunogen | Recombinant Human PI3-Kinase p85 α protein |
| Abbre | PI3-Kinase p85 α |
| Synonyms | GRB, IMD, AGM, PIK3R, AGM7, GRB1, IMD36, p85, p85-ALPHA, PI3 Kinase p85 alpha, PIK3R1, p85 alpha, P85A, Phosphatidylinositol 3 kinase, Phosphatidylinositol 3 kinase associated p 85 alpha, Phosphatidylinositol 3 kinase regulatory 1, Phosphatidylinositol 3-kinase 85 kDa regulatory subunit alpha, Phosphatidylinositol 3-kinase regulatory subunit alpha, Phosphoinositide 3 kinase, PI3 kinase p85 subunit alpha, PI3K, PI3K regulatory subunit alpha, PI3-kinase regulatory subunit alpha, PI3-kinase subunit p85-alpha, polypeptide 1 (p85 alpha), PtdIns 3 kinase p85 alpha, PtdIns-3-kinase regulatory subunit alpha, PtdIns-3-kinase regulatory subunit p85-alpha, regulatory subunit, regulatory subunit 1 (alpha), PI3 Kinase P85α |
| Swissprot | |
| Calculated MW | 84 kDa |
| Observed MW |
84 kDa
Western blotting is a method for detecting a certain protein in a complex sample based on the specific binding of antigen and antibody. Different proteins can be divided into bands based on different mobility rates. The mobility is affected by many factors, which may cause the observed band size to be inconsistent with the expected size. The common factors include: 1. Post-translational modifications: For example, modifications such as glycosylation, phosphorylation, methylation, and acetylation will increase the molecular weight of the protein. 2. Splicing variants: Different expression patterns of various mRNA splicing bodies may produce proteins of different sizes. 3. Post-translational cleavage: Many proteins are first synthesized into precursor proteins and then cleaved to form active forms, such as COL1A1. 4. Relative charge: the composition of amino acids (the proportion of charged amino acids and uncharged amino acids). 5. Formation of multimers: For example, in protein dimer, strong interactions between proteins can cause the bands to be larger. However, the use of reducing conditions can usually avoid the formation of multimers. If a protein in a sample has different modified forms at the same time, multiple bands may be detected on the membrane. |
| Cellular Localization | nucleus,cytoplasm,cis-Golgi network,cytosol,plasma membrane,cell-cell junction,phosphatidylinositol 3-kinase complex,phosphatidylinositol 3-kinase complex, class IA,membrane,perinuclear endoplasmic reticulum membrane, |
| Concentration | 0.2 mg/mL |
| Buffer | PBS, 50% glycerol, 0.05% Proclin 300, 0.05% protein protectant. |
| Purification Method | Protein A |
| Research Areas | Signal Transduction, Cancer, Immunology, Metabolism |
| Clone No. | 11D9 |
| Conjugation | Unconjugated |
| Storage | Store at -20°C Valid for 12 months. Avoid freeze / thaw cycles. |
| Shipping | Ice bag |
| background | Phosphatidylinositol 3-kinase phosphorylates the inositol ring of phosphatidylinositol at the 3-prime position. The enzyme comprises a 110 kD catalytic subunit and a regulatory subunit of either 85, 55, or 50 kD. This gene encodes the 85 kD regulatory subunit. Phosphatidylinositol 3-kinase plays an important role in the metabolic actions of insulin, and a mutation in this gene has been associated with insulin resistance. Alternative splicing of this gene results in four transcript variants encoding different isoforms. |
Other Clones
{{antibodyDetailsPage.numTotal}} Results
-
{{item.title}}
Citations ({{item.publications_count}}) Manual MSDS
Cat.No.：{{item.cat}}
{{index}} {{goods_show_value}}
Other Formats
{{formatDetailsPage.numTotal}} Results
Unconjugated
-
{{item.title}}
Citations ({{item.publications_count}}) Manual MSDS
Cat.No.：{{item.cat}}
{{index}} {{goods_show_value}}
-
IF：{{item.impact}}
Journal：{{item.journal}} ({{item.year}})
DOI：{{item.doi}}Reactivity：{{item.species}}
Sample Type：{{item.organization}}
-
Q{{(FAQpage.currentPage - 1)*pageSize+index+1}}:{{item.name}}
